Napo Pharmaceuticals, Inc. focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace — every country, every population, every channel — regardless of social or economic status. Napo’s mission is to provide novel medicines to high-margin western markets, while leveraging economies of scale in emerging and developing markets. We are committed to ensuring sustainable access to our drugs for 80% of the world’s population normally excluded from novel drug access, through existing and new partnerships with local pharmaceutical companies and distribution organizations, as well as with relief organizations to address disaster situations, such as the cholera outbreak in Haiti. Napo’s unique business model provides long-term sustainability. Napo will work with local organizations to commercialize in emerging and developing countries. The access created in such local markets is sustainable — no donations, charity, or grants are required.
Location: United States, California, San Francisco
Employees: 11-50
Founded date: 2002
Investors 2
| Date | Name | Website |
| - | Westlake V... | westlakevp... |
| - | Palm Cove ... | palmcoveca... |
Mentions in press and media 16
| Date | Title | Description |
| 05.07.2022 | Jaguar Health Appoints Senior Healthcare and Investment Executive Dr. Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee to Assess Opportunities for Alliances, Me... | Greg Divis departs from Jaguar's Board of Directors; Experienced business development executive Rachel Zolot Schwartz chairs new committee SAN FRANCISCO, CA / ACCESSWIRE / July 5, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today anno... |
| 22.06.2022 | Jaguar Health Announces Online Availability of a Presentation on Short Bowel Syndrome (SBS) by Dr. Mohamad Miqdady at Elite Ped-GI Congress in Abu Dhabi | SAN FRANCISCO, CA / ACCESSWIRE / June 22, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that a presentation by Dr. Mohamad Miqdady on short bowel syndrome (SBS) at the Elite Ped-GI Congress, which took place May 19-21, 2022 in Ab... |
| 31.03.2022 | Jaguar Health Enters Exclusive Crofelemer Distribution and License Agreement with Quadri Pharmaceuticals Store for Multiple Target Indications in Middle East Markets | Agreement grants Quadri Pharmaceuticals Store exclusive promotional, commercialization, and distribution rights in Bahrain, Kuwait, Qatar, Saudi Arabia, the United Arab Emirates, and Oman for human indications of crofelemer approved in the ... |
| 19.11.2021 | Jaguar Health : Announces Topline Results of Investigator-Initiated Phase 2 Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients | Crofelemer is a novel, oral plant-based non-opioid antidiarrheal medication SAN FRANCISCO, CA / ACCESSWIRE / November 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced topline results of the third-party, investigator-initiated Ph... |
| 03.01.2017 | Napo Pharmaceuticals Raises $2 Million from Kingdon Capital Management | SAN FRANCISCO--(BUSINESS WIRE)--Napo Pharmaceuticals, Inc., announced today that it has obtained $2 million in secured convertible debt financing from New York-based Kingdon Capital Management, LLC. Proceeds from the financing will primaril... |
| 03.01.2017 | Napo Pharmaceuticals Raises $2 Million from Kingdon Capital Management | SAN FRANCISCO--(BUSINESS WIRE)--Napo Pharmaceuticals, Inc., announced today that it has obtained $2 million in secured convertible debt financing from New York-based Kingdon Capital Management, LLC. Proceeds from the financing will primaril... |
| 30.04.2012 | FDA extends review of SLXP diarrhea drug; Napo explores new indications | There’s no indication that there is a problem with the application and the FDA did not request any additional studies. But it’s the second extension Salix has received in the last week. The FDA last week notified the company of a three-mont... |
| 07.02.2012 | Priority review for SLXP diarrhea drug, but shouldn’t patients have it by now? | Raleigh, North Carolina-based Salix had a busy 2011 and most of that activity was unrelated to crofelemer. Besides some licensing deals and acquisitions, the company has had its hands full with another gastrointestinal drug. Salix had expec... |
| 14.12.2011 | Salix files NDA for diarrhea drug despite dispute with partner Napo | Salix licensed crofelemer in 2008 from San Francisco, California drug developer Napo Pharmaceuticals, an agreement that paid Napo $4.5 million and called for Salix to be responsible for development of the compound. Crofelemer had been grant... |
| 09.05.2011 | Salix sued by partner for ‘breach’ over HIV-associated diarrhea drug | Salix disclosed the lawsuit Monday morning. The company said in a prepared statement that the lawsuit is baseless and Napo’s claims are without merit. Salix added that it plans to continue with the development and commercialization of the d... |
Show more